zolpidem tartrate(redirected from Tovalt ODT)
Pharmacologic class: Imidazopyridine
Therapeutic class: Sedative-hypnotic
Controlled substance schedule IV
Pregnancy risk category B
Depresses CNS by binding to gamma-aminobutyric acid receptors
Oral spray: 5 mg/actuation
Tablets: 5 mg, 6.25 mg, 10 mg, 12.5 mg
Tablets (sublingual): 1.75 mg, 3.5 mg, 5 mg, 10 mg
⊘Indications and dosages
Adults: 10 mg P.O. (Ambien) or 12.5 mg P.O.(Ambien CR), or 10 mg (Edluar) sublingual, or 10 mg oral spray (two sprays) immediately before bedtime
➣ As-needed use for treatment of insomnia when middle-of-the-night awakening is followed by difficulty returning to sleep
Adults: 1.75 mg (Intermezzo) sublingually for women and 3.5 mg (Intermezzo) sublingually for men, taken only once per night if needed
• Hepatic impairment
• Concurrent use of CNS depressants
• Elderly or debilitated patients
• Long-term treatment of insomnia
• Insomnia related to selective serotonin reuptake inhibitors
• Postoperative sedation
• Hypersensitivity to drug
Use cautiously in:
• pulmonary disease, hepatic or severe renal impairment
• history of psychiatric illness, suicide attempt, or substance abuse
• elderly or debilitated patients
• pregnant or breastfeeding patients
• children (safety not established).
• Don't give with or immediately after a meal.
CNS: amnesia, ataxia, confusion, euphoria, vertigo, daytime drowsiness, dizziness, drugged feeling
EENT: diplopia, abnormal vision
GI: nausea, vomiting, diarrhea, dry mouth
Other: hypersensitivity reaction, physical or psychological drug dependence, drug tolerance
Drug-drug.Antihistamines, opioid analgesics, phenothiazines, sedative-hypnotics, tricyclic antidepressants: increased CNS depression
Ketoconazole, ritonavir: increased blood level and enhanced effects of zolpidem
Rifampin: decreased zolpidem efficacy
Drug-herbs.Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors.Alcohol use: increased CNS depression
• Monitor for physical and psychological drug dependence. Watch for drug hoarding.
• Assess for adverse reactions, including confusion, ataxia, and amnesia.
• Tell patient to take immediately before bedtime (and not after a meal), because it works quickly.
• Instruct patient to place sublingual tablet under the tongue, where it will disintegrate; tell patient not to swallow tablet and not to take it with water.
• Instruct patient that oral spray pump needs to be primed initially and after not using spray for 14 days. Tell patient to fully press down on pump to make sure a full dose (5 mg) of oral spray is sprayed directly into the mouth over the tongue with each spray.
• Advise patient to take only when he is able to get a full night's sleep (7 to 8 hours) before he needs to be active again. Tell patient to use oral spray only if 4 hours of bedtime remain before planned time of waking.
• Stress that drug is meant only for short-term use (7 to 10 days).
• Tell patient rebound insomnia may occur for 1 to 2 nights after he discontinues drug.
• Inform patient that drug may cause amnesia, drowsiness, and a drugged feeling the next day.
• Caution patient to avoid driving and other hazardous activities while under drug's influence.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.